Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO)

J Ovarian Res. 2019 May 25;12(1):50. doi: 10.1186/s13048-019-0525-1.

Abstract

Introduction: The management of Serous Tubal Intraepithelial Carcinoma (STIC) found at the time of Risk-Reducing Salpingo-Oophorectomy (RRSO) remains unclear. We set out to analyse the incidence of peritoneal carcinomas developed after prophylactic surgery and to formulate further guidance for these patients.

Methods: This is a retrospective study of 300 consecutive RRSO performed at the Royal Marsden Hospital between January 2008 and January 2017.

Results: The median age at RRSO was 47.8 years (range 34 to 60 years) and median BMI was 26.2 kg/m2 (range 16 to 51 kg/m2). A total of 273 patients (91%) were tested for BRCA mutations. Of these, 124 (45.4%) had a BRCA 1 mutation, 118 (43.2%) had a BRCA 2 mutation, 2 (0.7%) had both a BRCA 1 and a BRCA 2 mutation and 29 (10.6%) had no BRCA mutation detected. Isolated STIC lesions were identified in 7 cases (2.3%) and p53 signatures in 75 cases (25%). There were five (1.6%) incidental tubal carcinomas and one (0.3%) ovarian carcinoma at the time of surgery. Two (28.6%) of the 7 patients with STIC identified following RRSO had high grade serous peritoneal carcinoma diagnosed at 53 and 75 months. One (0.3%) patient from the other 287 patients from our series with no STIC diagnosis or incidental carcinomas at RRSO developed high grade serous carcinoma of peritoneal origin after 92 months.

Conclusion: This study demonstrates that when a STIC lesion is identified following RRSO there is a significantly higher risk of a subsequent peritoneal cancer. Although there is no published consensus in literature, we recommend that consideration should be given for long term follow-up if a STIC lesion is identified at RRSO.

Keywords: BRCA; Peritoneal carcinoma; Risk-reducing Salpingo-oophorectomy; Serous tubal intraepithelial carcinoma.

MeSH terms

  • Adult
  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Cystadenocarcinoma, Serous / epidemiology*
  • Cystadenocarcinoma, Serous / genetics
  • Cystadenocarcinoma, Serous / prevention & control
  • Cystadenocarcinoma, Serous / secondary*
  • Fallopian Tube Neoplasms / genetics
  • Fallopian Tube Neoplasms / pathology*
  • Fallopian Tube Neoplasms / surgery*
  • Female
  • Humans
  • Incidence
  • Middle Aged
  • Mutation
  • Ovariectomy
  • Peritoneal Neoplasms / epidemiology*
  • Peritoneal Neoplasms / genetics
  • Peritoneal Neoplasms / prevention & control
  • Peritoneal Neoplasms / secondary*
  • Prophylactic Surgical Procedures
  • Retrospective Studies
  • Salpingectomy

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA2 protein, human